FENC FENNEC PHARMACEUTICALS INC.

FENC financial statements, revenue, balance sheet, cash flow, and SEC filings

CIK: 1211583 Exchange: Nasdaq SIC: 2836 (Biological Products, (No Diagnostic Substances)) Latest filing: 10-Q filed Nov 12, 2026 Data checked: Nov 13, 2026
Showing 3 of 28 annual and 0 of 63 quarterly periods. Full history available with a free account or via API.

▼ Company Profile

Filer Category
Non-accelerated filer<br>Smaller reporting company
Entity Type
Operating
Public Float
$106.05M (Jun 2025)
Industry (SIC)
2836 Biological Products, (No Diagnostic Substances)
Incorporated
A1
Fiscal Year End
December (1231)
Phone
(919) 636-4530
EIN
000000000
Headquarters
RESEARCH TRIANGLE PARK, NC, 27709
Public Float History
Market value of shares held by public investors, reported in annual DEI filings.
Former Names: ADHEREX TECHNOLOGIES INC (2002–2014)

▼ Key Metrics (TTM)

As of Sep 30, 2026
Financials
Revenue
$66.37M
Net Income
$2.03M
Total Assets
$83.54M
Total Equity
$49.19M
Total Debt
-
Free Cash Flow
-
Ratios
Operating Margin
5.6%
Net Margin
3.1%
Return on Equity
4.1%
Return on Assets
2.4%
Current Ratio
6.11x

▼ FY 2025 Summary Analysis

Annual report ending Dec 31, 2025

Overview and Growth

Fiscal 2025 results for FENNEC PHARMACEUTICALS INC. combined $44.64M of revenue with net loss of $9.74M and an operating cash outflow of $12.47M. The $44.64M revenue base provides substantial context for the company’s earnings, cash generation, and capital requirements. The top line contracted 6.1% from $47.54M in fiscal 2024; this top-line contraction left the company with a smaller revenue base. On a per-share basis, diluted EPS was -$0.34, which connects the reported earnings outcome with the company’s diluted share count. Diluted shares averaged 28.58M; this is the reported share base over which the company’s diluted per-share earnings were spread. The diluted share count was 4.7% higher than fiscal 2024, when diluted shares averaged 27.29M, adding context to the EPS comparison. At period end, total assets were $70.55M, framing the scale of the company’s operating and financing commitments. Revenue equaled 0.63x of total assets, indicating how much reported top-line activity the company produced relative to its period-end asset base.

Profitability

The reported operating result was an operating loss of $6.28M, reflecting costs that exceeded gross profit. The operating loss equaled 14.1% of revenue, showing the scale of the operating deficit relative to sales. The company ended the period with a net loss of $9.74M, extending the operating result through all remaining items. Measured against revenue, the bottom-line deficit represented 21.8% after all recognized items. The pretax result was a loss of $9.63M, establishing the deficit before tax effects. Pretax margin was -21.6%, reflecting a pre-tax loss equal to 21.6% of revenue. Income tax expense totaled $106.00K, providing the reported tax component that separates pretax and after-tax earnings. Relative to period-end equity, the net loss represented 27.5%. The loss-to-assets relationship was 13.8%, placing the bottom-line deficit against the company’s resource base. The net loss widened to $9.74M from $436.00K in fiscal 2024.

Liquidity and Capital Structure

At period end, the $70.55M asset base was financed through $35.08M of liabilities and $35.47M of equity. The near-term balance sheet paired $67.04M of current assets with $10.52M of current liabilities at the reporting date. At 6.37x, the current ratio shows that short-term assets were greater than short-term liabilities at period end. Cash and equivalents totaled $36.79M, identifying the most liquid reported component available within the broader current-asset balance. Cash and equivalents represented 349.8% of current liabilities, showing the portion of near-term obligations matched by reported cash alone. The equity-to-assets relationship was 50.3%, placing book capital against the total resource base. Relative to total assets, liabilities measured 49.7%, complementing the separate equity-based view of the company’s capital structure. Cash and equivalents equaled 52.1% of total assets, showing the liquid cash component within the company’s broader resource base. Compared with $44.95M in fiscal 2024, the current asset base moved 57.0% and finished higher. Compared with $26.63M in fiscal 2024, the current cash balance moved 38.1% and finished higher.

Cash Flow and Earnings Quality

The company reported an operating cash outflow of $12.47M, rather than cash generation from operations. A current operating cash outflow of $12.47M replaced the $26.98M inflow reported in fiscal 2024.
Based on the annual report for the fiscal year ending Dec 31, 2025. Analysis generated .
Sources and calculation details

Reported values are preserved. Derived values use the listed inputs; unavailable inputs remain blank.

Field-level sources for this historical record are unavailable until it is rebuilt from SEC facts.

Annual financial statements for FENNEC PHARMACEUTICALS INC.
Metric FY2025 📄 FY2024 📄 FY2023 📄
Income Statement
REVENUE
Revenue $44.64M $47.54M $21.25M
Cost of Revenue - - $1.26M
Gross Profit - - $19.99M
OPERATING EXPENSES
R&D Expense $250.00K $307.00K $56.00K
SG&A Expense $28.29M $23.05M $20.59M
Other Operating Expenses (derived) - - $12.12M
Operating Income $-6.28M $2.57M $-12.77M
NON-OPERATING INCOME / EXPENSE
Interest Expense $2.08M $4.07M $3.39M
Interest Income $787.00K $1.68M $441.00K
Other Income/Expense $-3.35M $-2.64M $-3.27M
Pretax Income $-9.64M $-71.00K $-16.05M
Income Tax $106.00K $365.00K -
Net Income $-9.74M $-436.00K $-16.05M
PER SHARE & SUPPLEMENTAL
Diluted EPS $-0.34 $-0.02 $-0.60
Diluted Shares 28.58M 27.29M 26.57M
Balance Sheet
ASSETS
Cash & Equivalents $36.79M $26.63M $13.27M
Other Current Assets $1.73M $466.00K $44.00K
Current Assets $67.04M $44.12M $26.86M
Other Noncurrent Assets $717.00K $822.00K $6.00K
Noncurrent Assets $3.51M $822.00K $6.00K
Total Assets $70.55M $44.95M $26.86M
LIABILITIES
Accounts Payable $4.64M $3.24M $3.78M
Current Liabilities $10.52M $6.92M $7.55M
Long-term Debt - $19.34M $30.93M
Other Noncurrent Liabilities (derived) - $24.56M $2.00K
Noncurrent Liabilities $24.56M $43.90M $30.93M
Total Liabilities $35.08M $50.82M $38.49M
EQUITY
Common Stock $189.91M $145.61M $144.31M
Additional Paid-in Capital $73.75M $66.96M $62.07M
Retained Earnings $-229.42M $-219.68M $-219.25M
Accumulated OCI $1.24M $1.24M $1.24M
Total Equity $35.47M $-5.87M $-11.62M
Total Liabilities & Equity $70.55M $44.95M $26.86M
SUPPLEMENTAL
Shares Outstanding 34.16M 27.53M 27.03M
Check: A − (L + E + Temp. Equity) - - -
Cash Flow Statement
Cash from Operations $-12.47M $26.98M $-17.14M
Capital Expenditures - - -
Cash from Investing $0 $0 $0
Cash from Financing $22.63M $-13.62M $6.64M
Free Cash Flow - - -
Beginning Cash (CFS) $26.63M $13.27M $23.77M
Net Change in Cash $10.15M $13.37M $-10.51M
Effect of FX on Cash $0 $0 $0
Calculated Ending Cash $36.79M $26.63M $13.27M
Cash per BS $36.79M $26.63M $13.27M
Cash scope difference (CFS − BS) - - -
Cash per CFS $36.79M $26.63M $13.27M

Create a free account to see full history, quarterly data, charts, CSV downloads, and API access.

Create Free Account Log In
🔒

Quarterly data and charts require a free account

Get access to 8 quarters of data, interactive charts, CSV downloads, and API access.

▼ Frequently Asked Questions

What is FENNEC PHARMACEUTICALS INC.'s annual revenue?

FENNEC PHARMACEUTICALS INC. reported $66.37M in revenue for trailing twelve months (ending September 2026). Revenue figures are sourced from the company's annual SEC EDGAR filing.

Is FENNEC PHARMACEUTICALS INC. profitable?

Yes. FENNEC PHARMACEUTICALS INC. reported $2.03M in net income for trailing twelve months. Profitability data is based on the company's most recent annual report filed with the SEC.